What is Cancer News Daily?

Cancer News Daily is a comprehensive cancer research news aggregator that collects and curates the latest research articles from 120+ trusted medical journals and cancer research institutions worldwide. We provide free access to breakthrough treatments, clinical trials, nutrition research, and new technology in oncology.

How often is content updated?

Our automated system fetches new cancer research articles every 2 hours from 120+ authoritative medical journals across 5 continents, ensuring you always have access to the latest breakthroughs.

What sources does Cancer News Daily aggregate from?

We aggregate content from 120+ trusted sources including top-tier journals like Nature Cancer, The Lancet Oncology, JAMA Oncology, Cancer Cell, major cancer centers like MD Anderson and Memorial Sloan Kettering, government organizations like NCI and NIH, and international research institutions across North America, Europe, Asia-Pacific, and beyond.

Is Cancer News Daily free to use?

Yes, Cancer News Daily is completely free to access. We believe life-saving cancer research should be accessible to everyone - patients, caregivers, researchers, and medical professionals worldwide.

Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8+ T cells

Journal for ImmunoTherapy of Cancer | March 4, 2026 | Yang, Y., He, J., Liang, T., Li, K., Lin, Y., Wang, H., Xi, W., Ye, S., Qiu, D., Xie, C., Hao, Y., Li, T., Yue, S., Ye, L., Chen, X.

Background The efficacy of combined chemotherapy and programmed cell death protein-1 (PD-1) immune checkpoint blockade (ICB) is constrained by the collateral cytotoxicity of chemotherapy toward proliferating tumor-specific CD8+ T (TTST) cells, a population indispensable for antitumor immunity. This study aimed to overcome this limitation by targeting a potential chemotherapy-resistant immune cell reservoir. Methods By using the murine acutely resolved lymphocytic…

Topics: immunotherapy, chemotherapy, research

Read the full article at Journal for ImmunoTherapy of Cancer